MANKIND Q1 FY27 results at a glance
MANKIND PHARMA LIMITED Q1 FY27 key results metrics| Quarter | Q1 FY27 |
|---|
| Quarter ended | 30 Jun 2026 |
|---|
| Revenue | ₹4,031 cr |
|---|
| Revenue YoY | +12.9% |
|---|
| Operating profit | ₹830 cr |
|---|
| Operating margin | 20.6% |
|---|
| Net profit | ₹568 cr |
|---|
| Net profit YoY | +29.6% |
|---|
| Net profit QoQ | +2.5% |
|---|
| Net margin | 14.1% |
|---|
| Basic EPS | ₹13.76 |
|---|
| TTM revenue | ₹14,611 cr |
|---|
| TTM net profit | ₹1,969 cr |
|---|
| TTM net margin | 13.5% |
|---|
MANKIND Q1 FY27 results: what the numbers say
MANKIND PHARMA LIMITED (MANKIND) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹4,031 cr and a net profit of ₹568 cr, translating into earnings per share of ₹13.76.
Compared with the same quarter a year earlier, revenue grew by +12.9% and net profit grew strongly by +29.6%. Profit rising faster than revenue points to better cost control or operating leverage flowing through the P&L.
Operating profit for the quarter stood at ₹830 cr, an operating margin of 20.6% versus 17.6% a year ago — a gain of 3.0 percentage points.
MANKIND quarter-wise results table
Revenue
₹4,031 cr
+12.9% YoY
Net profit
₹568 cr
+29.6% YoY
Operating profit
₹830 cr
+32.2% YoY
MANKIND PHARMA LIMITED (MANKIND) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q1 FY272026-06-30 | ₹4,031 cr | ₹830 cr | ₹568 cr | 20.6% | 14.1% | ₹13.76 | +29.6% | +2.5% |
| Q4 FY262026-03-31 | ₹3,443 cr | ₹707 cr | ₹554 cr | 20.5% | 16.1% | ₹13.44 | +31.7% | +35.6% |
| Q3 FY262025-12-31 | ₹3,567 cr | ₹697 cr | ₹409 cr | 19.5% | 11.5% | ₹9.90 | — | -6.7% |
| Q1 FY262025-06-30 | ₹3,570 cr | ₹628 cr | ₹438 cr | 17.6% | 12.3% | ₹10.62 | — | +4.2% |
| Q4 FY252025-03-31 | ₹3,079 cr | ₹452 cr | ₹421 cr | 14.7% | 13.7% | ₹10.20 | — | — |
| TTM (last 4 quarters) | ₹14,611 cr | ₹2,862 cr | ₹1,969 cr | 19.6% | 13.5% | ₹47.72 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
MANKIND quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
MANKIND PHARMA LIMITED quarterly income statement| Particulars | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q1 FY262025-06-30 | Q4 FY252025-03-31 |
|---|
| Revenue / Sales | ₹4,031 cr | ₹3,443 cr | ₹3,567 cr | ₹3,570 cr | ₹3,079 cr |
|---|
| Total expenses | ₹3,200 cr | ₹2,736 cr | ₹2,870 cr | ₹2,942 cr | ₹2,627 cr |
|---|
| Gross profit | ₹2,932 cr | ₹2,485 cr | ₹2,589 cr | ₹2,517 cr | ₹2,204 cr |
|---|
| Operating profit (EBIT) | ₹830 cr | ₹707 cr | ₹697 cr | ₹628 cr | ₹452 cr |
|---|
| Operating margin | 20.6% | 20.5% | 19.5% | 17.6% | 14.7% |
|---|
| Interest cost | ₹110 cr | ₹142 cr | ₹157 cr | ₹171 cr | ₹191 cr |
|---|
| Profit before tax | ₹769 cr | ₹659 cr | ₹509 cr | ₹540 cr | ₹515 cr |
|---|
| Tax expense | ₹195 cr | ₹99.75 cr | ₹95.12 cr | ₹95.87 cr | ₹86.44 cr |
|---|
| Effective tax rate | 25.4% | 15.1% | 18.7% | 17.7% | 16.8% |
|---|
| Net profit (PAT) | ₹568 cr | ₹554 cr | ₹409 cr | ₹438 cr | ₹421 cr |
|---|
| Net profit margin | 14.1% | 16.1% | 11.5% | 12.3% | 13.7% |
|---|
| Basic EPS | ₹13.76 | ₹13.44 | ₹9.90 | ₹10.62 | ₹10.20 |
|---|
| Diluted EPS | ₹13.74 | ₹13.41 | ₹9.89 | ₹10.60 | ₹10.18 |
|---|
MANKIND results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q1 FY26 | Q4 FY25 |
|---|
| Revenue YoY | +12.9% | +11.8% | — | — | — |
|---|
| Revenue QoQ | +17.1% | -3.5% | -0.1% | +15.9% | — |
|---|
| Operating profit YoY | +32.2% | +56.3% | — | — | — |
|---|
| Operating profit QoQ | +17.5% | +1.4% | +10.9% | +38.9% | — |
|---|
| Net profit YoY | +29.6% | +31.7% | — | — | — |
|---|
| Net profit QoQ | +2.5% | +35.6% | -6.7% | +4.2% | — |
|---|
| EPS YoY | +29.6% | +31.8% | — | — | — |
|---|
| EPS QoQ | +2.4% | +35.8% | -6.8% | +4.1% | — |
|---|
MANKIND annual results history
Full-year performance for MANKIND PHARMA LIMITED, useful for reading each quarter in context.
MANKIND PHARMA LIMITED annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹14,278 cr | ₹12,207 cr | ₹10,259 cr | ₹8,749 cr |
|---|
| Total expenses | ₹11,443 cr | ₹9,691 cr | ₹8,020 cr | ₹7,108 cr |
|---|
| Gross profit | ₹10,128 cr | ₹8,638 cr | ₹7,002 cr | ₹5,787 cr |
|---|
| Operating profit (EBIT) | ₹2,835 cr | ₹2,516 cr | ₹2,239 cr | ₹1,642 cr |
|---|
| Operating margin | 19.9% | 20.6% | 21.8% | 18.8% |
|---|
| Interest cost | ₹633 cr | ₹421 cr | ₹27.82 cr | ₹40.27 cr |
|---|
| Profit before tax | ₹2,333 cr | ₹2,516 cr | ₹2,398 cr | ₹1,671 cr |
|---|
| Tax expense | ₹395 cr | ₹510 cr | ₹457 cr | ₹362 cr |
|---|
| Effective tax rate | 16.9% | 20.3% | 19.1% | 21.6% |
|---|
| Net profit (PAT) | ₹1,913 cr | ₹1,991 cr | ₹1,913 cr | ₹1,282 cr |
|---|
| Net profit margin | 13.4% | 16.3% | 18.6% | 14.7% |
|---|
| Basic EPS | ₹46.35 | ₹49.28 | ₹47.75 | ₹32.00 |
|---|
| Diluted EPS | ₹46.28 | ₹49.19 | ₹47.68 | ₹32.00 |
|---|
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹4,031 cr against ₹3,570 cr in Q1 FY26, and ₹3,443 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue grew +17.1%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹3,200 cr, or 79.4% of revenue, with operating profit grew +32.2% year on year.
Margins, tax and profitability
Net profit of ₹568 cr works out to a net margin of 14.1% compared with 12.3% in the year-ago quarter. Margin expansion of this kind usually reflects a better product or service mix, softer input costs, or tighter overheads.
Below the operating line, MANKIND PHARMA LIMITED reported profit before tax of ₹769 cr, a tax charge of ₹195 cr (effective rate 25.4%), interest cost of ₹110 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹554 cr in Q4 FY26 to ₹568 cr in Q1 FY27, a change of +2.5%.
Trailing twelve months and annual context
Across the trailing four quarters MANKIND PHARMA LIMITED has generated revenue of ₹14,611 cr and net profit of ₹1,969 cr, a trailing net margin of 13.5%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹14,278 cr with net profit of ₹1,913 cr and EPS of ₹46.35, versus the prior year where revenue grew +17.0% and profit declined -3.9%.
What to watch in the next MANKIND quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
MANKIND PHARMA LIMITED has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
MANKIND results coverage
No results report published for MANKIND yet — our desk covers each quarter within minutes of the filing.
More on MANKIND
MANKIND quarterly results FAQs
What were MANKIND PHARMA LIMITED (MANKIND) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), MANKIND PHARMA LIMITED reported revenue of ₹4,031 cr and net profit of ₹568 cr, a change of +29.6% year on year on +12.9% revenue growth. EPS stood at ₹13.76.
What is MANKIND profit margin in Q1 FY27?
MANKIND PHARMA LIMITED posted a net profit margin of 14.1% and an operating margin of 20.6% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹14,611 cr and net profit ₹1,969 cr.
Did MANKIND results beat the previous quarter?
MANKIND PHARMA LIMITED net profit changed +2.5% quarter on quarter, from ₹554 cr in Q4 FY26 to ₹568 cr in Q1 FY27.
When are MANKIND PHARMA LIMITED (MANKIND) quarterly results?
MANKIND PHARMA LIMITED has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see MANKIND latest quarterly results?
Results coverage for MANKIND will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the MANKIND stock page.
What is MANKIND PHARMA LIMITED annual revenue and profit?
For FY26, MANKIND PHARMA LIMITED reported full-year revenue of ₹14,278 cr and net profit of ₹1,913 cr, with EPS of ₹46.35.
How many quarterly results has MANKIND declared recently?
Past results dates for MANKIND will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 10 Sept 2026. For information only, not investment advice.
